Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Hammer SM, Squires KE, Hughes MD.
et al. A controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. N Engl J Med.1997;337:725-728.
Palella Jr FJ, Delaney KM, Moorman AC.
et al. Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature.1995;373:123-126.
Wei X, Ghosh SK, Taylor ME.
et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature.1995;3:117-122.
Perelson AS, Essunger P, Cao Y.
et al. Decay characteristics of HIV-1-infected compartments during combination
Montaner JSG, Reiss P, Cooper D.
et al. A randomized double-blind trial comparing combinations of nevirapine,
didanosine, and zidovudine for HIV-infected patients. JAMA.1998;279:930-937.
Wong JK, Hezareh M, Gunthard HF.
et al. Recovery of replication-competent HIV despite prolonged suppression
of plasma viremia. Science.1997;278:1291-1295.
Finzi D, Hermankova M, Pierson T.
et al. Identification of a reservoir for HIV-1 in patients on highly active
anti-retroviral therapy. Science.1997;278:1295-1300.
Chun TW, Stuyver L, Mizell SB.
et al. Presence of an inducible HIV-1 latent reservoir during highly active
anti-retroviral therapy. Proc Natl Acad Sci U S A.1997;94:13193-13197.
Zhang H, Dornadula G, Beumont M.
et al. HIV-1 in the semen of men receiving highly active anti-retroviral therapy. N Engl J Med.1998;339:1803-1839.
Furtado MR, Callaway DS, Phair JP.
et al. Persistence of HIV-1 transcription in peripheral blood mononuclear
cells in patients receiving potent antiretroviral therapy. N Engl J Med.1999;340:1614-1622.
Zhang L, Ramratnam B, Tenner-Racz K.
et al. Quantifying residual HIV-1 replication in patients receiving combination
antiretroviral therapy. N Engl J Med.1999;340:1605-1613.
Cavert W, Notermans DW, Staskus K.
et al. Kinetics of response in lymphoid tissues to antiretroviral therapy
of HIV-1 infection. Science.1997;276:960-964.
Natarajan V, Bosche M, Metcalf JA.
et al. HIV-1 replication in patients with undetectable plasma virus receiving
Hockett RD, Kilby JM, Derdeyn CA.
et al. Constant mean viral copy number per infected cell in tissues regardless
of high, low or undetectable plasma HIV RNA. J Exp Med.1999;189:1545-1554.
LaFeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue
of patients with sustained plasma RNA of <200 copies/ml. J Infect Dis.1998;177:235-238.
Martinez MA, Cababa M, Ibanez A, Clotet B, Arno A, Ruiz L. Human immunodeficiency virus type 1 genetic evolution in patients with
prolonged depression of plasma viremia. Virology.1999;256:180-187.
Pomerantz RJ, delaMonte SM, Donegan SP.
et al. Human immunodeficiency virus infection of the uterine cervix. Ann Intern Med.1988;108:321-327.
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform
extraction. Anal Biochem.1987;162:156-159.
Zhang H, Zhang Y, Spicer TP.
et al. Reverse transcription takes place within extracellular HIV-1 virions. AIDS Res Hum Retroviruses.1993;9:1287-1296.
Zhang H, Dornadula G, Wu Y.
et al. Kinetic analysis of intravirion reverse transcription in the blood
plasma of human immunodeficiency virus type 1–infected individuals. J Virol.1996;70:628-634.
Zhang H, Dornadula G, Pomerantz RJ. Endogenous reverse transcription of human immunodeficiency virus type
1 in physiological microenvironments. J Virol.1996;70:2809-2824.
Raboud JM, Montaner JSG, Conway B.
et al. Suppression of plasma viral load below 20 copies/ml is required to
achieve along term response to therapy. AIDS.1998;12:1619-1624.
Harrigan PR, Whaley M, Montaner JSG. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS.1999;13:F59-F62.
Montaner JSG, Harris M, Mo T, Harrigan PR. Rebound of plasma HIV viral load following prolonged suppression with
combination therapy. AIDS.1998;12:1398-1399.
Lisziewicz J, Rosenberg E, Lieberman J.
et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med.1999;340:1683.
Garcia F, Plana M, Vidal C.
et al. Dynamics of viral load rebound and immunological changes after stopping
effective antiretroviral therapy. AIDS.1999;13:F79-F86.
Pomerantz RJ. Residual HIV-1 disease in the era of highly active antiretroviral therapy. N Engl J Med.1999;340:1672-1674.
Pomerantz RJ. HIV in semen and other reservoirs during effective HAART. HIV Adv Res Ther.1999;9:17-24.
Finzi D, Blankson J, Siciliano JE.
et al. Latent infection of CD4+ T-cells provides a mechanism for
lifelong persistence of HIV-1 even in patients on effective combination therapy. Nat Med.1999;5:512-517.
Ho DD, Pomerantz RJ, Kaplan JC. Pathogenesis of infection with human immunodeficiency virus. N Engl J Med.1987;317:278-286.
Enting RH, Hoetelmans RMW, Lange JMA, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. AIDS.1998;12:1941-1955.
Zhu T, Wang N, Carr A.
et al. Genetic characterization of human immunodeficiency virus type 1 in
blood and genital secretions. J Virol.1996;70:3098-3107.
Zhang Z-Q, Schuler T, Wietgrefe S.
et al. Sexual transmission and propagation of SIV and HIV-1 in activated and
quiescent T cells. In: Program and abstracts of the Sixth Conference on Retroviruses
and Opportunistic Infections; February 1-4, 1999; Chicago, Ill. Abstract 206.
Lewin SR, Vesanen M, Hurley KA.
et al. Use of real-time PCR and molecular beacons to detect virus replication
in human immunodeficiency virus type 1-infected individuals on prolonged effective
antiretroviral therapy. J Virol.1999;73:6099-6103.
Markowitz M, Vesanan M, Tenner-Racz K.
et al. The effect of commencing combination antiretroviral therapy soon after
human immunodeficiency virus type 1 infection on viral replication and antiviral
immune responses. J Infect Dis.1999;179:525-537.
Grossman Z, Tolis M, Feinberg M.
et al. Ongoing HIV dissemination during HAART. Nat Med.1999;5:1099-1103.
Chun T-W, Engel D, Mizell SB.
et al. Effect of interleukin-2 on the pool of latently infected resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral
therapy. Nat Med.1999;5:651-655.